To Immunize Pts w Extensive Stage SCLC Combined w Chemo w or w/oAll Trans Retinoic Acid - Full Text View

Sponsor:	H. Lee Moffitt Cancer Center and Research Institute
Collaborator:	Introgen Therapeutics
Information provided by (Responsible Party):	H. Lee Moffitt Cancer Center and Research Institute
ClinicalTrials.gov Identifier:	NCT00617409

Purpose

The purpose of this research study is to test a tumor (cancer) vaccine given along with chemotherapy to determine if this vaccine will increase the chances of the tumor shrinking and/or the amount of time that people who have this disease will live.

Condition	Intervention	Phase
Small Cell Lung Cancer	Drug: Paclitaxel Biological: Drug: Ad.p53-DC vaccines Drug: ATRA	Phase II

Study Type:	Interventional
Study Design:	Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Factorial Assignment Masking: Open Label Primary Purpose: Treatment
Official Title:	A Randomized Phase II Trial Using Dendritic Cells Transduced With an Adenoviral Vector Containing the p53 Gene to Immunize Patients With Extensive Stage Small Cell Lung Cancer in Combination With Chemotherapy With or Without All Trans Retinoic Acid

Resource links provided by NLM:

Genetics Home Reference related topics: Li-Fraumeni syndrome Help Me Understand Genetics

MedlinePlus related topics: Cancer Lung Cancer

Drug Information available for: Paclitaxel Tretinoin

U.S. FDA Resources

Further study details as provided by H. Lee Moffitt Cancer Center and Research Institute:

Primary Outcome Measures:

Number of Participants With Tumor Response in Each Group [ Time Frame: 24 months ] [ Designated as safety issue: No ]
To evaluate the efficacy of second line chemotherapy (single agent paclitaxel) after progression following the Ad.p53-DC vaccine, with (Arm C) and without (Arm B) ATRA, or after observation (ARM A). That is, to estimate the objective tumor response rate for each treatment group. Tumor response will be assessed via radiographic imaging which will occur after every 2 cycles of chemotherapy (paclitaxel). Tumor response will be defined as partial response (PR) or complete response (CR).

Secondary Outcome Measures:

Number of Participants With Overall Survival (OS) in Each Group [ Time Frame: 24 months ] [ Designated as safety issue: Yes ]
To evaluate the survival of all patients enrolled on an intent-to-treat basis, with a comparison made between the 3 arms.

Estimated Enrollment:	81
Study Start Date:	October 2007
Estimated Study Completion Date:	October 2012
Estimated Primary Completion Date:	October 2012 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
Active Comparator: Observation (Standard of Care) + Second Line Chemotherapy Group A - Observation, standard of care. All groups wil receive paclitaxel as second line chemotherapy (chemo) if their cancer spreads.	Drug: Paclitaxel All groups wil receive paclitaxel as second line chemotherapy if their cancer spreads. At any point when a patient develops evidence of progressive disease, the patient will be treated with second-line chemotherapy. Paclitaxel will be given at a dose of 200 mg/m² on day 1 of 21 day cycles. Other Names: Antitumor agent Chemotherapy
Experimental: Ad.p53-DC vaccines + Second Line Chemotherapy Group B - Leukopheresis, vaccines x 3, rescan if stable repeat leukopheresis + three more vaccines. All groups will receive paclitaxel as second line chemotherapy if their cancer spreads.	Drug: Paclitaxel All groups wil receive paclitaxel as second line chemotherapy if their cancer spreads. At any point when a patient develops evidence of progressive disease, the patient will be treated with second-line chemotherapy. Paclitaxel will be given at a dose of 200 mg/m² on day 1 of 21 day cycles. Other Names: Antitumor agent Chemotherapy Biological: Drug: Ad.p53-DC vaccines Patients randomized to Arm B will receive vaccinations on 3 occasions, at 2 week intervals. 1-5x106 p53 positive DCs in 1 ml will be injected intradermally into 4 separate sites (0.25 ml injected at each site), in bilateral proximal upper and lower extremities (in the regions of the axillary and inguinal nodal basins). Patients will be restaged approximately 2-3 weeks after vaccine # 3 (first vaccine course). If patients show no sign of disease progression at restaging, then a second leukopheresis will be performed. Patients will then be vaccinated 3 more times (second vaccine course) at 4-week intervals, for a total of 6 possible vaccines. Restaging will occur 2-4 weeks after completing the second vaccine course. Patients in Arm C will receive vaccines at the same dose and schedule as described for patients in Arm B. In addition, they will receive 150 mg/m² of ATRA for 3 days prior to each vaccine administration (followed by vaccine administration on the fourth day). Other Name: INGN 225
Experimental: Ad.p53-DC vaccines + ATRA + Second Line Chemo Group C - Leukopheresis, ATRA pills with vaccine x 3, re-scan, stable-repeat leukopheresis plus ATRA pills with vaccine x 3-Rescan. All groups wil receive paclitaxel as second line chemotherapy if their cancer spreads.	Drug: Paclitaxel All groups wil receive paclitaxel as second line chemotherapy if their cancer spreads. At any point when a patient develops evidence of progressive disease, the patient will be treated with second-line chemotherapy. Paclitaxel will be given at a dose of 200 mg/m² on day 1 of 21 day cycles. Other Names: Antitumor agent Chemotherapy Biological: Drug: Ad.p53-DC vaccines Patients randomized to Arm B will receive vaccinations on 3 occasions, at 2 week intervals. 1-5x106 p53 positive DCs in 1 ml will be injected intradermally into 4 separate sites (0.25 ml injected at each site), in bilateral proximal upper and lower extremities (in the regions of the axillary and inguinal nodal basins). Patients will be restaged approximately 2-3 weeks after vaccine # 3 (first vaccine course). If patients show no sign of disease progression at restaging, then a second leukopheresis will be performed. Patients will then be vaccinated 3 more times (second vaccine course) at 4-week intervals, for a total of 6 possible vaccines. Restaging will occur 2-4 weeks after completing the second vaccine course. Patients in Arm C will receive vaccines at the same dose and schedule as described for patients in Arm B. In addition, they will receive 150 mg/m² of ATRA for 3 days prior to each vaccine administration (followed by vaccine administration on the fourth day). Other Name: INGN 225 Drug: ATRA The patients in Arm C will receive vaccines at the same dose and schedule as described for patients in Arm B. In addition, they will receive 150 mg/m² of ATRA for 3 days prior to each vaccine administration (followed by vaccine administration on the fourth day). Other Names: All Trans Retonic Acid tretinoin Vesanoid INGN 225

Detailed Description:

After initial diagnosis patients will be treated with a standard platinum/etoposide regimen. This standard first-line chemotherapy may/will be administered to patients under the direction of their primary medical oncologist inside or outside of the Moffitt Cancer Center. Patients will receive the platinum drug on day 1 and etoposide on days 1-3 of each 21-day cycle for 4-6 cycles. Patients who have progressive disease at this point are changed to second line chemotherapy, and will not be eligible to participate in this clinical trial. Patients who achieve a complete response, partial response, or stable disease (CR, PR, or SD) after standard first-line chemotherapy will be enrolled. Radiographic studies and tumor measurements are repeated 3-6 weeks after the last dose of chemotherapy (+/- PCI) and may be repeated after prophylactic cranial irradiation (PCI) at the discretion of the principal investigator (PI) and treating physician.

PCI will be permitted at the discretion of the treating oncologist(s). The initial radiation consultation and simulation should occur as soon as the final staging has occurred. Ideally, treatment should commence 1-2 weeks after final staging has been confirmed and will be administered in 10-15 fractions over a 2-3 week period, as recommended by the treating radiation oncologist. Although steroid use is not prohibited, it is recommended and preferred that they not be used during PCI (steroids will have to be discontinued ≥ 2 weeks before first vaccination). PCI can also be considered between vaccines #4 and #5 or vaccine #5 and #6 in those patients eligible for the second course of vaccinations. Systemic dose of steroids will NOT be allowed in these cases unless strictly necessary and after discussion with the PI.

Patients who achieve CR, PR or SD after the completion of first line chemotherapy +/- PCI will be screened for initial registration. Screening tests and procedures will be performed approximately 4-6 weeks after the completion of first line chemotherapy or 6-9 weeks after completion of PCI. Ideally, screening should be completed 1-2 weeks prior to leukopheresis.

Patients who successfully complete the screening exams for initial registration will be randomized into one of three study arms.

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria at the time of initial registration:

Patients must have a histologically confirmed diagnosis of Small Cell Lung Cancer (SCLC)
Must have extensive stage SCLC
Must have completed first line chemotherapy: 4-6 cycles of a standard platinum/etoposide regimen and PCI if chosen at the discretion of the treating Oncologist
Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
Acceptable (adequate) organ function including:
- White blood count (WBC) >2,500/mm³ and Absolute neutrophil count (ANC) >1,200/mm³
- Platelets > 75,000/mm³
- Hematocrit > 24% OR Hemoglobin ≥8.5g/dl
- Bilirubin < 2.0 mg/dl
- Creatinine < 2.0 mg/dl
- Aspartic transaminase (AST/SGOT) ≤2 x upper limit of normal (ULN)
- Alkaline phosphatase ≤3 x ULN
Patients must have achieved responsive or non-progressive disease status (stable disease [SD], partial response [PR], or complete response [CR]) assessed 4-6 weeks after the last cycle of first line chemotherapy. SD, PR or CR may be confirmed after completion of prophylactic cranial irradiation (PCI) at the discretion of the principal investigator (PI) after discussion with the treating oncologist.
Males and Females of reproductive potential must agree to use effective contraception during the study and for at least 4 weeks after the last dose of ATRA. Patients are instructed and agree to notify the principal investigator should a pregnancy occur for themselves or their partner.
Willing and able to sign written informed consent and be able to comply with the study protocol for the duration of the study

Exclusion Criteria at the time of initial registration:

Patients with severe, uncontrolled intercurrent illness or infection
Anticipated requirement for systemic chronic steroid use at the time of vaccination, unless specifically indicated for dose supplementation or replacement of established corticosteroid insufficiency
Receiving systemic doses of corticosteroids should have them discontinued ≥ 2 weeks prior to starting vaccination (this include patients receiving steroids with PCI). Inhaled steroids should also be discontinued if at all possible. Chronic, stable doses of inhaled steroids for the treatment of chronic obstructive pulmonary disease (COPD), etc. are allowed if in the opinion of the treating physician(s) they cannot be stopped.
Any pre-existing immunodeficiency condition, or a known history of human immunodeficiency virus (HIV), Hepatitis B or Hepatitis C
Uncontrolled and/or symptomatic central nervous system (CNS) metastasis
Pregnant or lactating women. A pregnancy test-serum BHCG will be obtained during the screening process.
Have received any chemotherapy other than the first line chemotherapy specified in the study protocol: standard platinum/etoposide regimen
Have received any prior investigational drugs including immunotherapy, gene therapy, hormone therapy, biologic therapy for treatment of SCLC
Any known pre-existing autoimmune disorder
History of a second malignancy within the previous 3 years. Exceptions include: non-melanoma skin cancers, any in-situ carcinomas and successfully treated early stage malignancies without evidence of recurrence for > 18 months.
Have not recovered from any chemotherapy-related or other therapy-related toxicity at study entry
Have had major surgery without full recovery or major surgery within 3 weeks of the start of vaccine treatment
Patients with other significant diseases or disorders that, in the Investigator's opinion, would exclude them from the study

Pre-Pheresis Criteria:

Patients must have had a successful harvest of peripheral blood mononuclear cell (PBMC) with leukopheresis at least 6-10 weeks after chemotherapy.
ECOG performance status of 0-2
The last dose of first line chemotherapy must have been administered at least 4 weeks prior to the first vaccine administration.
Patients who received radiation therapy: last dose of radiation must have been completed at least 2 weeks prior to the first vaccine administration and the patient must have recovered from the toxic effects of the treatment prior to study enrollment (except for alopecia)
Patients who received steroid therapy: last steroid dose must have been given at least 2 weeks prior to the first vaccine administration
Adequate organ function:
- WBC > 2,500/mm³ and ANC >1,200/mm³
- Platelets > 75,000/mm³
- Hematocrit > 25%
- Hemoglobin ≥9g/dl
- Bilirubin < 2.0 mg/dl
- Creatinine < 2.0 mg/dL
- AST/SGOT ≤ 2 x ULN
- Alkaline phosphatase < 3 x ULN
Patients must have signed informed consent at initial registration.
HLA-A*0201 Testing as determined by flow cytometry followed by molecular analysis of a peripheral blood specimen, however this result will not be an inclusion criterion

Pre-Paclitaxel Eligibility:

Progressive disease after observation (Arm A) or vaccinations (Arms B and C)
ECOG performance status of 0-2
Adequate organ function:
- WBC > 2,500/mm³ and ANC >1,200/mm³
- Platelets > 75,000/mm³
- Hematocrit > 25%
- Hemoglobin ≥9g/dl
- Bilirubin < 2.0 mg/dl
- Creatinine < 2.0 mg/dL
- AST/SGOT ≤ 2 x ULN
- Alkaline phosphatase < 3 x ULN

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00617409

Locations

United States, Florida
H. Lee Moffitt Cancer Center & Research Institute
Tampa, Florida, United States, 33612

Sponsors and Collaborators

H. Lee Moffitt Cancer Center and Research Institute

Introgen Therapeutics

Investigators

Principal Investigator:

Alberto Chiappori, M.D.

H. Lee Moffitt Cancer Center and Research Institute

More Information

Additional Information:

Moffitt Cancer Center Clinical Trials website This link exits the ClinicalTrials.gov site

No publications provided

Responsible Party:	H. Lee Moffitt Cancer Center and Research Institute
ClinicalTrials.gov Identifier:	NCT00617409 History of Changes
Other Study ID Numbers:	MCC-15206, 105790, 0147NE, 0705-857
Study First Received:	February 5, 2008
Last Updated:	January 5, 2012
Health Authority:	United States: Food and Drug Administration

Keywords provided by H. Lee Moffitt Cancer Center and Research Institute:

SCLC
vaccine
immunize

Additional relevant MeSH terms:

Lung Neoplasms
Small Cell Lung Carcinoma
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Neoplasms
Lung Diseases
Respiratory Tract Diseases
Carcinoma, Bronchogenic
Bronchial Neoplasms
Antineoplastic Agents

Tretinoin
Paclitaxel
Therapeutic Uses
Pharmacologic Actions
Keratolytic Agents
Dermatologic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents, Phytogenic

ClinicalTrials.gov processed this record on February 09, 2012